Study #2021-0925
REStoring lymphoCytes Using NKTR-255 after chemoradiothErapy in solid tumors (RESCUE)
MD Anderson Study Status
Enrolling
Treatment Agent
NKTR-255, Durvalumab
Description
To learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lung Cancer
Study phase:
Phase II
Physician name:
Steven Lin
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.